Keith Anthony Jones bought $5,620 of HUMA
director at Humacyte, Inc.. 10,000 shares at an average of $0.56, traded Sep 14, 2026, filed Sep 15, 2026.
Score components
- +15RoleDirector
- 0Trade size$6k at market
- +6Relative to holdingsHoldings up 25%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001193125-26-391889, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Sep 14, 2026 | POpen-market purchase Common Stock | +10,000 | $0.56 | $5,620 | 50,000 | 27 d ago |
Related signals
Other insiders at Humacyte, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 68Notable | Humacyte, Inc. | Brady W Dougan director | $3.7M 2,241,045 shares | -100% | |
| 78Notable | Humacyte, Inc. | Laura E Niklason President, CEO and Director | $3.7M 2,241,045 shares | -100% | |
| 44Moderate | Humacyte, Inc. | William John Scheessele Chief Commercial Officer | $9,999 6,493 shares | +42% | |
| 46Moderate | Humacyte, Inc. | Shamik J Parikh Chief Medical Officer | $12k 7,500 shares | - | |
| 60Notable | Humacyte, Inc. | Dale A. Sander CFO and Chief Corp. Deve. Off. | $31k 20,000 shares | +97% | |
| 58Moderate | Humacyte, Inc. | Michael T. Constantino director | $20k 16,000 shares | +94% | |
| 58Moderate | Humacyte, Inc. | Charles Bruce Green director | $7,740 6,000 shares | +250% | |
| 66Notable | Humacyte, Inc. | Kathleen Sebelius director | $66k 50,000 shares | +121% | |
| 21Weak | HUMAbuy Humacyte, Inc. | Michael T. Constantino director | $20k 4,600 shares | +37% | |
| 18Weak | Humacyte, Inc. | Brady W Dougan director | $7,979 1,797 shares | +1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.